Your session is about to expire
← Back to Search
Behavioural Intervention
An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis
N/A
Waitlist Available
Research Sponsored by Click Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Itch NRS ≥ 4 during screening
Aged 18 years or older
Must not have
Planning the introduction of new therapies during the 7-week study period
Anticipating a change in current pharmacological or psychotherapy treatment regimen during the 7-week study period
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 5
Summary
This trial tests a software to help patients with skin conditions like atopic dermatitis and psoriasis by improving brain functions related to various aspects of health.
Who is the study for?
This trial is for individuals with skin conditions like atopic dermatitis, eczema, or psoriasis. Participants should be interested in trying a digital intervention aimed at reducing scratching behavior.
What is being tested?
The study tests two versions of CT-100, a software platform with interactive components designed to disrupt scratching by targeting neural systems related to various sensory and cognitive processes.
What are the potential side effects?
Since this is a digital intervention involving software-based therapeutic components, traditional physical side effects are not expected. Users may experience eye strain or mental fatigue.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My itchiness level is 4 or higher.
Select...
I am 18 years old or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I plan to start new treatments within the next 7 weeks.
Select...
I plan to change my current medication or therapy within the next 7 weeks.
Select...
I currently have a skin infection.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 5
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 5
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Dermatology Life Quality Index
Change in Peak Pruritus Numerical Rating Scale
Change in Quality of Life symptoms
+3 moreSecondary study objectives
Frequency of Adverse Events
Frequency of Serious Adverse Events
Severity of Adverse Events
+1 moreTrial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: CT-100-004-A PsoriasisExperimental Treatment1 Intervention
Group II: CT-100-004-A Atopic DermatitisExperimental Treatment1 Intervention
Group III: CT-100-004-B PsoriasisPlacebo Group1 Intervention
Group IV: CT-100-004-B Atopic DermatitisPlacebo Group1 Intervention
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for psoriasis include TNF-alpha inhibitors, methotrexate, cyclosporine, and phototherapy. TNF-alpha inhibitors work by blocking tumor necrosis factor-alpha, a cytokine involved in systemic inflammation, thereby reducing the inflammatory response in psoriasis.
Methotrexate inhibits dihydrofolate reductase, leading to reduced DNA synthesis and cell proliferation, which helps control the rapid skin cell turnover in psoriasis. Cyclosporine suppresses the immune system by inhibiting calcineurin, reducing T-cell activation and subsequent inflammation.
Phototherapy uses ultraviolet light to slow skin cell growth and reduce scaling and inflammation. These treatments are crucial for psoriasis patients as they target the underlying inflammatory and immune processes, providing symptom relief and improving quality of life.
While DiNaMo components focus on neural system modulation, the common psoriasis treatments primarily target immune and inflammatory pathways, highlighting the multifaceted approach needed for effective management.
A systematic review of evidence based treatments for lichen simplex chronicus.
A systematic review of evidence based treatments for lichen simplex chronicus.
Find a Location
Who is running the clinical trial?
Click Therapeutics, Inc.Lead Sponsor
16 Previous Clinical Trials
2,778 Total Patients Enrolled
Shaheen LakhanStudy DirectorClick Therapeutics
4 Previous Clinical Trials
415 Total Patients Enrolled